| Execution period | Vesting after 1 year; maximum exercise period of 10 years |
|---|
BSE filing, NSE: RAINBOW. Summary written from the filing by ALFA Finder's alert engine.
Rainbow Childrens Medicare Ltd: key numbers
- Share price
- ₹1,204.80
- Market cap
- ₹12,237 Cr
- Revenue (annual)
- ₹1,703 Cr
- Net profit (annual)
- ₹278.3 Cr
- P/E (TTM)
- 42.9×Sector 52.0×
- Promoter holding
- 49.83%-0.01% QoQ
- FII holding
- 14.66%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rainbow Childrens Medicare Ltd
All →Rainbow Childrens Medicare Board Meeting Date
Rainbow Children's Medicare will hold a board meeting on 31-Oct-2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the results.
Rainbow Childrens Medicare Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Rainbow Childrens Medicare Capacity Expansion
Rainbow Children’s Medicare entered a 60-year lease for 2 acres in Amaravati with APCRDA. The site will house a new 250-bed super speciality children’s hospital.
- From
- Andhra Pradesh Capital Region Development Authority (APCRDA)
- Execution
- 60 years
- hospital beds
- 250.0 beds
Rainbow Childrens Medicare Credit Rating
ICRA Limited has reaffirmed the [ICRA] AA (Stable) issuer rating for Rainbow Children's Medicare Limited. This periodic rating review confirms the company's existing credit standing.
Rainbow Childrens Medicare Management Change
Rainbow Childrens Medicare Limited has appointed Mr. Sudarshan Patodia as the Chief Financial Officer, effective September 23, 2026.
Rainbow Childrens Medicare Employee Stock Options
Rainbow Children's Medicare Limited granted 55,690 stock options to eligible employees under its ESOP 2025 scheme.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.